secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031252
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback
--------------------------------------------------------------------------------

- Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.
- G&A expenses $2.4M, down 17% YoY; R&D expenses $4.9M, down 19% YoY.
- Ovaprene Phase 3 contraceptive study recruiting at 20 U.S. sites; ~125 women expected to complete 6 months by Q2 2025.
- Sildenafil Cream Phase 3 design pending additional FDA feedback; each Phase 3 study estimated at ~$15M.
- Total grants received for DARE-LARC1 now ~$29.3M; pipeline includes DARE-HRT1 in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/0001493152-24-031252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer